PATENT CLAIM ANALYSIS

Application Number: 16335765
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["546", "070000"]

Abstract:
A method for treating small cell lung cancer (SCLC). In the method, a therapeutically effective amount of a compound of Formula I: wherein R 1 , R 2  and R 3  have the definitions disclosed in the specification is administered alone or in combination with one or more anticancer agents, or surgery, radiation therapy, chemotherapy, and/or targeted therapy.

Claim (Index 14):
The method of  claim 8 , wherein the second anticancer agent is selected from the group consisting of anti-microtubule agents (such as diterpenoids and vinca alkaloids like vinorelbine); platinum coordination complexes; alkylating agents (such as nitrogen mustards like ifosphamide, oxazaphosphorines, alkylsulfonates, nitrosoureas (including 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU)), busulfan, chloroambucil, cyclophosphamide, iphosphamide, melphalan, streptozocin, thiotepa, uracil nitrogen mustard, triethylenemelamine, temozolomide, and triazenes); antibiotic agents or plant alkaloids (such as cryptophycins, daunorubicin, doxorubicin, idarubicin, irinotecan, L-asparaginase, mitomycin-C, mitramycin, navelbine, paclitaxel, docetaxel, topotecan, vinblastine, vincristine, teniposide (VM-26), and etoposide (VP-16), anthracyclins, actinomycins (such as actinomycin-D) and bleomycins); topoisomerase II inhibitors (such as epipodophyllotoxins); hormones or steroids (such as 5\u03b1-reductase inhibitor, aminoglutethimide, anastrozole, bicalutamide, chlorotrianisene, diethylstilbestrol (DES), dromostanolone, estramustine, ethinyl estradiol, flutamide, fluoxymesterone, goserelin, hydroxyprogesterone, letrozole, leuprolide, medroxyprogesterone acetate, megestrol acetate, methyl prednisolone, methyltestosterone, mitotane, nilutamide, prednisolone, arzoxifene (SERM-3), tamoxifen, testolactone, testosterone, triamicnolone, and zoladex); synthetics (such as all-trans retinoic acid, carmustine (BCNU), carboplatin (CBDCA), lomustine (CCNU), cis-diaminedichloroplatinum (cisplatin), dacarbazine, gliadel, hexamethylmelamine, hydroxyurea, levamisole, mitoxantrone, o,p\u2032-dichlorodiphenyldichloroethane (o,p\u2032-DDD) (also known as lysodren or mitotane), oxaliplatin, porfimer sodium, procarbazine, and imatinib mesylate (Gleevec\u00ae)); antimetabolites (such as chlorodeoxyadenosine, cytosine arabinoside, 2\u2032-deoxycoformycin, fludarabine phosphate, 5-fluorouracil (5-FU), 5-fluoro-2\u2032-deoxyuridine (5-FUdR), gemcitabine, camptothecin, 6-mercaptopurine, methotrexate, 4-methylthioamphetamine (4-MTA), thioguanine, pemetrexed, purine and pyrimidine analogues and anti-folate compounds); biologies (such as alpha interferon, BCG ( Bacillus  Calmette-Guerin), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and herceptin); topoisomerase I inhibitors (such as camptothecins; hormones and hormonal analogues); signal transduction pathway inhibitors (such as tyrosine receptor inhibitors like erlotinib; EGFR inhibitors like gefitinib and afatinib; TNFR inhibitors like denosumab); non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; epigenetic or transcriptional modulators (such as histone deacetylase inhibitors); DNA replication or transcription inhibitors (such as picoplatin); DNA damage response (DDR) inhibitors (such as Poly(ADP-ribose) polymerase (PARP) inhibitors (e.g., Talazoparib ((8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one), Veliparib (HY-10130; 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide), Olaparib (4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one, Niraparib 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide), and Rucaparib (8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one)) or PI3K/AKT pathway inhibitors (e.g., LY294002 2-Morpholin-4-yl-8-phenylchromen-4-one), buparlisib (5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine), and alpelisib ((2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide)); and cell cycle signaling inhibitors.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 99.0
- Lexical Diversity: 1.33333
- Patent Class: 546.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13549572', '15745639', '13504943', '15309382', '11490438']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.796735780210528
- 35 USC 102 Novelty (BERT): 0.5434075077795563
- Combined Prediction Score: 0.7714029529674309
- Mean Citation Score: 272.06953000000004
- Max Citation Score: 401.5671
- Similarity Product: 257.93212915282845

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test